BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2584153)

  • 1. Potentiation of cytotoxicity and antitumor activity of adenosine analogs by the adenosine deaminase inhibitor adecypenol.
    Tanaka H; Kawakami T; Yang ZB; Komiyama K; Omura S
    J Antibiot (Tokyo); 1989 Nov; 42(11):1722-4. PubMed ID: 2584153
    [No Abstract]   [Full Text] [Related]  

  • 2. Adecypenol, a unique adenosine deaminase inhibitor containing homopurine and cyclopentene rings. Taxonomy, production and enzyme inhibition.
    Omura S; Ishikawa H; Kuga H; Imamura N; Taga S; Takahashi Y; Tanaka H
    J Antibiot (Tokyo); 1986 Sep; 39(9):1219-24. PubMed ID: 3781920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adecypenol, a unique adenosine deaminase inhibitor containing homopurine and cyclopentene rings.
    Omura S; Tanaka H; Kuga H; Imamura D
    J Antibiot (Tokyo); 1986 Feb; 39(2):309-10. PubMed ID: 3957791
    [No Abstract]   [Full Text] [Related]  

  • 4. Toxicities of adenosine and 2'-deoxyadrenosine in L cells treated with inhibitors of adenosine deaminase.
    Lapi L; Cohen SS
    Biochem Pharmacol; 1977 Jan; 26(1):71-6. PubMed ID: 299815
    [No Abstract]   [Full Text] [Related]  

  • 5. Enhancement of the biological activity of cordycepin (3'-deoxyadenosine) by the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Johns DG; Adamson RH
    Biochem Pharmacol; 1976 Jun; 25(12):1441-4. PubMed ID: 1084747
    [No Abstract]   [Full Text] [Related]  

  • 6. Adenosine deaminase inhibitors: their role in chemotherapy and immunosuppression.
    Glazer RI
    Cancer Chemother Pharmacol; 1980; 4(4):227-35. PubMed ID: 7002342
    [No Abstract]   [Full Text] [Related]  

  • 7. Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Adamson RH; Zaharevitz DW; Johns DG
    Pharmacology; 1977; 15(1):84-9. PubMed ID: 840892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a new adenosine deaminase inhibitor, isocoformycin, on toxicity, antitumor activity and tissue distribution of formycin A and 9-beta-D-arabinofuranosyladenine.
    Hidaka T; Katayama K; Yamashita K; Yamashita T; Watanabe K; Shimazaki M; Ohno M; Takeuchi T; Umezawa H
    J Antibiot (Tokyo); 1980 Mar; 33(3):303-9. PubMed ID: 7380742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenine arabinoside inhibition of adenovirus replication enhanced by an adenosine deaminase inhibitor.
    Wigand R
    J Med Virol; 1979; 4(1):59-65. PubMed ID: 119038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of adenosine deaminase to increase the antitumor activity of adenine nucleoside analogues.
    Plunkett W
    Ann N Y Acad Sci; 1985; 451():150-9. PubMed ID: 3907452
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased toxicity of 9-beta-D-arabinofuranosyladenine in the presence of an inhibitor of adenosine deaminase.
    Plunkett W; Cohen SS
    Ann N Y Acad Sci; 1977 Mar; 284():91-102. PubMed ID: 280161
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibitors of adenosine deaminase and the development of antiviral agents.
    Cohen SS
    Ann N Y Acad Sci; 1985; 451():204-14. PubMed ID: 2416257
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of adenosine deaminase inhibitors on the apparent rate of phosphorylation of deoxyadenosine.
    Deibel MR; Coleman MS; Hutton JJ
    Biochem Med; 1981 Jun; 25(3):288-97. PubMed ID: 6973972
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic effects of 9-beta-D-arabinofuranosyladenine and 2'-deoxycoformycin combinations on intracerebral leukemia.
    Lee SH; Caron N; Kimball AP
    Cancer Res; 1977 Jul; 37(7 Pt 1):1953-5. PubMed ID: 861931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biochemical pharmacology of (2'-R)-chloropentostatin, a novel inhibitor of adenosine deaminase.
    Jackson RC; Leopold WR; Ross DA
    Adv Enzyme Regul; 1986; 25():125-39. PubMed ID: 2433905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated T lymphocytes resist the toxic effects of the adenosine deaminase inhibitor, 2-deoxycoformycin.
    Kotb M; Veit BC
    Cell Immunol; 1982 Sep; 72(1):64-76. PubMed ID: 6983389
    [No Abstract]   [Full Text] [Related]  

  • 17. Two approaches that increase the activity of analogs of adenine nucleosides in animal cells.
    Plunkett W; Cohen SS
    Cancer Res; 1975 Jun; 35(6):1547-54. PubMed ID: 1079475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo inhibition of adenosine deaminase by 2'-deoxycoformycin in mouse blood and leukemia L1210 cells.
    Agarwal RP
    Biochem Pharmacol; 1980 Feb; 29(2):187-93. PubMed ID: 6965857
    [No Abstract]   [Full Text] [Related]  

  • 19. Hemolysis in mice treated with deoxycoformycin, an inhibitor of adenosine deaminase.
    Smith CM; Belch A; Henderson JF
    Biochem Pharmacol; 1980 Apr; 29(8):1209-10. PubMed ID: 6966932
    [No Abstract]   [Full Text] [Related]  

  • 20. Synergism between the antiproliferative activities of arabinosyladenine and N6-benzyladenosine.
    Tritsch GL; Nechaev A; Mittelman A
    Cancer Biochem Biophys; 1977; 2(2):87-90. PubMed ID: 567524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.